Stocks
Cartesian Therapeutics, Inc.RNAC
NASDAQHealthcareBiotechnology$6.22
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing mRNA cell therapies for autoimmune diseases, with its lead candidate, Descartes-08, targeting myasthenia gravis and other conditions. Investors track the stock for its progress in Phase 2 and Phase 3 trials and its potential to disrupt the autoimmune treatment market.
52W Range: $5.60-$11.00
Congressional Interest in Cartesian Therapeutics, Inc. (RNAC)
No congressional trades have been disclosed for Cartesian Therapeutics, Inc. (RNAC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RNAC?
No congressional trades found for this stock.